

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri - As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma











